U.S. authorities initiated a closer look at Chinese state support and pricing in the biotech sector, with the International Trade Commission (ITC) set to examine whether Chinese subsidies and pricing practices disadvantaged American biotech firms. The probe could lay groundwork for tariffs or other trade restrictions. BioCentury and U.S. filings cited potential links to market manipulation and government incentives in China’s life sciences ecosystem. The ITC investigation is a trade‑policy review, not a regulatory assessment of product safety; it examines whether imported goods and state actions materially harm domestic industries.